The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Phase III trial of camrelizumab plus rivoceranib and TACE in unresectable HCC
Stephen Lam Chan, MD, FRCP, Chinese University of Hong Kong, Hong Kong, China, discusses interim progression-free survival results from a Phase III randomized trial (NCT05320692) of camrelizumab and rivoceranib with transarterial chemoembolization (TACE) versus TACE alone in patients with TACE-eligible unresectable hepatocellular carcinoma (uHCC). Results demonstrated a statistically significant and clinically meaningful improvement in progression-free survival with the combination regimen, with consistent benefit across prespecified subgroups and a manageable safety profile, supporting this as a potential new treatment option in uHCC. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
For this abstract 4001, it’s also an RCT comparing the TCE plus the Camrelizumab and the rivoceranib versus those patients with the TCE alone. The result actually was very similar to the EMERALD-3, whereas there’s an improvement in the median progression-free survival, favoring the combination arm, and also numerically, there’s a higher radiological response rate...
For this abstract 4001, it’s also an RCT comparing the TCE plus the Camrelizumab and the rivoceranib versus those patients with the TCE alone. The result actually was very similar to the EMERALD-3, whereas there’s an improvement in the median progression-free survival, favoring the combination arm, and also numerically, there’s a higher radiological response rate.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
